Kodu・Aktsiate loetelu・Alkermes PLC

Alkermes PLC

Avatud

SektorTervishoid

49.33 -1.54

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

49.05

Max

50.66

Põhinäitajad
By Trading Economics
Sissetulek	-116M -66M
Müük	8.4M 393M
P/E Sektori keskmine	58.589 64.641
Aktsiakasum	0.38
Kasumimarginaal	-16.92
Töötajad	2,050
EBITDA	-98M -22M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+16.01% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	27. okt 2026

Turustatistika
By TradingEconomics
Turukapital	3.1B 8.8B
Eelmine avamishind	50.87
Eelmine sulgemishind	49.33

Uudiste sentiment

By Acuity

10%

90%

5 / 340 Pingereas Healthcare

Alkermes PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. aug 2026, 20:02 UTC

Alkermes shares are higher today, driven by significant gains in the overall market and major technology stocks, despite earlier session pullbacks.

31. juuli 2026, 19:36 UTC

Alkermes Plc shares are lower today, impacted by declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

30. juuli 2026, 19:58 UTC

Alkermes Plc shares are higher during Thursday's session, reflecting a broader recovery in tech shares despite remaining below the 20-day moving average.

29. juuli 2026, 20:03 UTC

News

Macro Event

Shares declining despite price target increases from JP Morgan, Baird.

28. juuli 2026, 20:02 UTC

News

Event

Alkermes Plc shares are lower after reporting second-quarter earnings of 0 cents per share, below the consensus estimate of 29 cents.

24. juuli 2026, 19:46 UTC

Alkermes Plc shares are lower today, pulling back after an early high. No specific news has been identified to explain the decline.

22. juuli 2026, 19:36 UTC

Alkermes Plc shares are lower today, despite an earlier session high, amid rising crude oil prices and concerns over potential supply disruptions.

21. juuli 2026, 18:46 UTC

Alkermes shares are higher today, supported by improved market sentiment and renewed interest in AI stocks. The asset is trading near its one-month range high.

20. juuli 2026, 22:01 UTC

Alkermes Plc shares declined after-market, retracing from earlier peaks. The asset is currently below its 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

Alkermes PLC Prognoos

Hinnasiht

By TipRanks

16.01% tõus

12 kuu keskmine prognoos

Keskmine 57.46 USD 16.01%

Kõrge 65 USD

Madal 38 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Alkermes PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi Alkermes PLC aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

5 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.